Slides
Page 1
Nissan Chemical CORPORATION WHERE IT ALL BEGINS Presentation for Investors 1Q FY2026 ( April 1 , 2026 - June 30 , 2026 ) Financial Results Translation of presentation materials for the conference call held on August 7 , 2026 Presented by DAIMON Hideki Director , Senior Executive Vice President & CFO August 7 , 2026 Create Together
Page 2
2 01 1Q FY2026 Financial Results P3 02 Segment Performance P11 03 ESG Topics P32 04 Appendix P37 C o n t e n t s
Page 3
3 C o n t e n t s 01 1Q FY2026 Financial Results P3
Page 4
4 1Q FY2026 Financial Summary Shareholder Returns ◼ Share repurchase plan: ¥10.5 billion between May 2026 and March 2027 (as announced in May 2026) 1Q vs. 1Q FY2025 ◼ Sales up ¥8.9 billion (+13%) ◼ OP up ¥3.8 billion (+21%) ◼ Net Income up ¥2.9 billion (+21%) ◼ Sales, OP and Net Income achieved record-high results 1Q vs. 1Q Outlook as of May 2026 ◼ Sales above target ¥9.7 billion ◼ OP above target ¥5.1 billion ◼ Net Income above target ¥3.0 billion FY2026 Outlook ◼ FY2026 Outlook for 1H and full year remain unchanged from those announced in May 2026 (Outlook by segment also remain unchanged)
Page 5
5 1Q FY2026 Financial Summary YOY Change 1Q FY2025 Actual 1Q FY2026 Actual YOY Change Sales 69.9 78.8 +8.9 (+13%) Operating Profit 18.1 21.9 +3.8 (+21%) Non-Operating Income/Expenses 0.0 1.7 +1.7 Foreign exchange Gains/Losses -0.7 0.4 +1.1 Ordinary Income 18.1 23.6 +5.5 (+30%) Extraordinary Income/Loss 0.0 0.0 0.0 Net Income1 13.9 16.8 +2.9 (+21%) EBITDA2 21.4 25.5 +4.1 EPS (¥/share) 102.20 125.74 +23.54 OP Margin 25.9% 27.8% +1.9pt FX Rate (¥/$) 145 160 - 1. Net Income = Profit Attributable to Owners of Parent 2. EBITDA = Operating Profit + Depreciation and amortization （¥billion）
Page 6
6 1Q FY2026 Financial Summary Compared to Outlook 1Q FY2026 Outlook 1Q FY2026 Actual vs. Outlook Sales 69.1 78.8 +9.7 (+14%) Operating Profit 16.8 21.9 +5.1 (+30%) Non-Operating Income/Expenses 1.4 1.7 +0.3 Foreign exchange Gains/Losses 0.0 0.4 +0.4 Ordinary Income 18.2 23.6 +5.4 (+30%) Extraordinary Income/Loss 0.0 0.0 0.0 Net Income1 13.8 16.8 +3.0 (+22%) EBITDA2 - 25.5 - EPS (¥/share) - 125.74 - OP Margin 24.3% 27.8% +3.5pt FX Rate (¥/$) 150 160 - （¥billion） 1. Net Income = Profit Attributable to Owners of Parent 2. EBITDA = Operating Profit + Depreciation and amortization
Page 7
7 Analysis of Changes in OP FY2024 Actual FY2023 Actual YOY Change Outlook as of May 2024 vs. Outlook 9.1billion -1.8 billion（-16%） -2.5 billion 2Q Chemicals vs. Outlook -1.3 billion YOY Change -0.4 billion Agro vs. Outlook -0.4 billionYOY Change -0.3 billion (fixed cost up 0.6 billion) Healthcare vs. Outlook +0.2 billionYOY Change flat 10.9billion （¥） Performance Materials vs. Outlook -1.5 billionYOY Change -1.4 billion (fixed cost up 1.0 billion) 11.6 billion Reference （Semis Materials -3.9 billion） （Semis Materials -2.6 billion） FY2026 Actual FY2025 Actual YOY Change Outlook as of May 2026 vs. Outlook 21.9billion +3.8billion(+21%) +5.1billion(+30%) 1Q Performance Materials vs. Outlook +2.4 billion YOY Change +2.5 billion OP increase due to sales increase in Semis Materials and Inorganic Materials OP increase due to sales increase in Semis Materials and Inorganic Materials Chemicals OP increase due to sales increase in Basic ChemicalsYOY Change +0.2 billion Healthcare YOY Change +0.2 billion 18.1billion Agrochemicals OP increase due to sales increase in ROUNDUP, VERDAD and GRACIA etc. vs. Outlook +1.6 billion YOY Change +0.2 billion 16.8 billion 1. Fixed cost etc.: including inventory adjustment cost vs. Outlook -0.1 billion vs. Outlook in line OP decrease due to fixed cost etc.1 up （¥） OP increase due to sales increase in Fluralaner, ALTAIR and GRACIA etc. OP increase due to sales increase in LIVALO and Custom Chemicals
Page 8
8 1Q FY2025 Actual 1Q FY2026 Actual YOY Change 1Q FY2026 Outlook Interest income, dividend income 0.64 1.00 +0.36 0.92 Equity in earnings of affiliates 0.23 0.40 +0.17 0.63 Foreign exchange gains/losses1 -0.67 0.43 +1.10 0.00 Interest expense -0.14 -0.13 +0.01 -0.18 Loss on disposal of non-current assets, others -0.02 0.04 +0.06 0.03 Non-Operating Income/Expenses 0.04 1.74 +1.70 1.40 Extraordinary Income 0.00 0.00 0.00 0.00 Extraordinary Losses 0.00 0.00 0.00 0.00 Extraordinary Income/Losses 0.00 0.00 0.00 0.00 Breakdown of Non-Operating Income/Expenses and Extraordinary Income/Losses 1. FX Rate (¥/$): 2025/3 149.53, 2025/6 144.82, 2026/3 159.93, 2026/6 162.45 （¥billion）
Page 9
9 1Q FY2025 Actual 1Q FY2026 Actual YOY Change CF from operating activities 16.3 21.2 +4.9 Income before income taxes & non-controlling interests 18.1 23.6 +5.5 Extraordinary losses (income) 0.0 0.0 0.0 Depreciation & amortization1 3.3 3.6 +0.3 Income taxes paid -8.9 -7.4 +1.5 Working capital, others 3.8 1.4 -2.4 CF from investing activities -3.3 -6.1 -2.8 Purchase of PPE2 -4.7 -4.4 +0.3 Purchase and sales of investment securities 0.0 -1.2 -1.2 Others 1.4 -0.5 -1.9 Free cash flow 13.0 15.1 +2.1 CF from financing activities -7.7 -16.7 -9.0 Payout to shareholders (dividend) -14.2 -17.7 -3.5 Payout to shareholders (share repurchase) -2.9 -4.7 -1.8 Liabilities with Interest 9.5 -4.1 -13.6 Others -0.1 9.8 +9.9 Effect of exchange rate change on cash & cash equivalents 0.7 0.2 -0.5 Change in cash & cash equivalents 6.1 -1.5 -7.6 Change in cash & cash equivalents resulting from change in scope of consolidation 0.0 0.9 +0.9 Cash & cash equivalents at end of period 33.5 35.2 +1.7 Free cash flow in 1Q FY2026 was ¥15.1 billion, an increase of ¥2.1 billion from 1Q FY2025 Cash Flows 1. Including amortization of goodwill 2. Including intangible assets （¥billion） 【申送り】 新しい項目の「連結範囲変更に伴う現金及び現金同等物の増減額」は、 正式には”Increase(decrease)~ “だが、 他の項目（現金及び現金同等物の増減額）と合わせて、”Change~“とした。
Page 10
10 Balance Sheets 2025/6 2026/3 2026/6 vs. 2026/3 Liabilities 98.9 96.0 104.8 +8.8 Accounts payable 19.5 22.6 23.8 +1.2 Borrowings, CP & Bonds 49.8 38.4 44.3 +5.9 Others 29.6 35.0 36.7 +1.7 Net assets 235.6 259.1 255.1 -4.0 Shareholders' equity1 219.8 238.8 233.6 -5.2 Valuation difference on available-for-sale securities 8.1 11.5 12.3 +0.8 Foreign currency translation adjustment 2.8 3.1 3.4 +0.3 Remeasurements of defined benefit plans 1.5 1.9 1.9 0.0 Non-controlling interests 3.4 3.8 3.9 +0.1 Total liabilities & net assets 334.5 355.1 359.9 +4.8 ▍Breakdown of Investment Securities 1. Change in shareholders’ equity -5.2 = Net Income 16.8 – Dividend and others 22.0 . 2. Net D/E Ratio = (Borrowings + CP + Bonds - Cash) / Shareholders' equity 3. 2026/3 22.0 + Acquisition 0.0 + Sales and valuation difference 1.2 = 2026/6 23.2 4. Strategic shareholdings on net assets = strategic shareholdings (Non-consolidated basis, Listed shares + Unlisted shares) / Net assets (Consolidated basis) 2025/6 2026/3 2026/6 vs. 2026/3 2018/3 Listed shares3 (Number of stocks held, Non-consolidated basis) 17.2 (24) 22.0 (24) 23.2 (24) +1.2 (0) 30.0 (55) Unlisted shares 2.2 2.5 3.6 +1.1 1.7 Subsidiaries/Associate shares 6.6 8.0 8.6 +0.6 6.8 Total 26.0 32.5 35.4 +2.9 38.5 2025/6 2026/3 2026/6 vs. 2026/3 Current assets 211.5 222.0 223.4 +1.4 Cash 33.5 35.7 35.2 -0.5 Accounts receivable 90.5 97.2 100.2 +3.0 Inventories 78.4 76.6 78.3 +1.7 Others 9.1 12.5 9.7 -2.8 Fixed assets 123.0 133.1 136.5 +3.4 Total PPE 73.8 77.0 78.8 +1.8 Intangible assets 13.1 12.8 12.1 -0.7 Investment securities 26.0 32.5 35.4 +2.9 Others 10.1 10.8 10.2 -0.6 Total assets 334.5 355.1 359.9 +4.8 （¥billion） Equity Ratio 69.4% 71.9% 69.8% Net D/E Ratio2 0.07 0.01 0.04 Strategic shareholdings on net assets4 7.4% 8.6% 9.6% 17.0% Reference
Page 11
11 C o n t e n t s 02 Segment Performance P11
Page 12
Performance Materials 12 58.8 63.0 65.5 71.6 81.7 82.6 84.6 100.1 113.4 126.1 14.2 15.0 17.0 22.4 27.6 25.4 22.5 29.3 35.3 38.6 24.1% 23.8% 26.0% 31.3% 33.8% 30.8% 26.6% 29.3% 31.1% 30.6% 0% 5% 10% 15% 20% 25% 30% 35% 40% 0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0 110.0 120.0 130.0 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025 FY2026E Sales OP OP Margin Overview ▍ Performance Materials – Recent Financial Performance1 （¥billion） ▍ FY2026 Outlook by Segment (¥billion) OP Agrochemicals 95.9 Performance Materials 109.7 Chemicals 39.6Healthcare 5.3 Others 21.7 Agrochemicals 26.0 Chemicals 0.8 Healthcare 1.5 Others -1.4 Performance Materials 32.1 Sales Reference Presentation for R&D of Performance Materials (June 21, 2022） 289.7 Agrochemicals 97.2 Performance Materials 126.1 Chemicals 41.4 66.8 Agrochemicals 27.0 Chemicals 1.3 Performance Materials 38.6 Healthcare 5.5 Others 19.5 Healthcare 1.1 Others -1.2 1. FY2025- : New OP method adopted. FY2024 Actual have been restated based on the new method.
Page 13
Performance Materials 13 Sales by Subsegment, EBITDA Margin Trend (No change from the May 2026 announcement) ◼ Semis Materials: High growth rates (YoY change) have been achieved from FY2024 onward, supported by the recovery of Semis market and our strong position in Asia following the temporary adjustment phase in FY2023 ◼ DP Materials: Recovered after bottom-out in FY2022, have maintained stable sales as Cash Cow ◼ In terms of sales composition by subsegment, Semis Materials, a growth driver, significantly surpass DP Materials ◼ All of the subsegments’ sales are increasing in FY2026, especially Semis Materials ▍ Sales of Performance Materials by Subsegment, Segment Total EBITDA Margin1 Trend 36% 34% 36% 37% 37% 0% 5% 10% 15% 20% 25% 30% 35% 40% FY2022 Actual FY2023 Actual FY2024 Actual FY2025 Actual FY2026 Outlook Inorganic Materials Display Materials Semis Materials Segment Total EBITDA Margin +6% -1% +2% +8% +27% +18% YOY change 1. EBITDA Margin= (Operating Profit + Depreciation and amortization) / Sales
Page 14
Performance Materials 14 2024 2030 ▍ Sales growth of our Semis Materials exceeding market growth +10% 2024-2030 CAGR Market Our Semis 2024-2030 CAGR +10pt~ outperform market growth (Composition） 51% 49% 45% 55% ~37% 63%~ +20%~ ▍ Sales Image of our Semis Materials （Composition ratio by generation） ▍ Sales Trend of Our Semis Materials1 2024-2030 CAGR +20%~ +26% (Upside Scenario) 1. SNOWTEX(polishing) (Inorganic Materials) and High-purity sulfuric acid (Chemicals) are not included(Fiscal Year) 2024-2030 CAGR +20%~ Growth Outlook for our Semis Materials (No change from the May 2026 announcement) ◼ Our Semis Materials sales growth rate is expected to be +20% or more (2024-2030 CAGR), exceeding the market growth rate of +10% ◼ Particularly for AI server applications, etc., our sales are expected to grow significantly in leading-edge and advanced generations The number of material layers tends to increase as technology generations advance 150 100 50 (¥billion) [Vertical axis] Number of wafers Converted to 12-inch wafer equivalents (Source: TechInsights Inc.) 【Leading-edge】 Logic：2nm and beyond, DRAM：Early 10nm generation and beyond, NAND：State-of-the-art as of 2025 【Advanced】 Logic：7nm – 3nm, DRAM：Mid-10nm generation, NAND：128 layers and above, but below leading-edge 【Legacy】 All other generations [Vertical axis] Sales Actual Image 2024 Actual 2026 Outlook 2030 Image ■Leading-edge ■Advanced ■Legacy [Vertical axis] Sales Leading-edge & advanced CAGR+22-24% , Legacy CAGR+13-15% 0
Page 15
Performance Materials 15 Sales Growth Rate of Main Products 1. EUV materials: Both Under-Layer and Si-HM for EUV Main Products 1Q FY2026 Actual YOY Change vs. Outlook Total Semis Materials +49% Above ARC® +35% Above Multi-layer process materials +96% Above EUV materials +23% Slightly Below Total Display Materials -4% In line Total Inorganic Materials +27% Above Total Segment +26% Above ◼ Semis Materials: 【1Q】 Sales YOY +49%, Sales above target ◼ DP Materials: 【1Q】 Sales YOY -4％, Sales in line with target ◼ Inorganic Materials: 【1Q】 Sales YOY +27%, Sales above target 半導体製品の英語表記について（2026年7月事業部へ確認済） 多層材料：Multi-Layer Process Materials (ハイフンが必要) SOC: Spin-On Carbon (ハイフンが必要) Si-HM: Silicon Hard Mask (SiliconとHardの間はハイフンは不要) EUV under-layer (ハイフンが必要) 3D Packaging process materials (Temporary bonding materials) →AdhesiveではなくBonding
Page 16
Performance Materials 16 1Q FY2026 Actual YOY Change (¥billion) 1Q FY2025 Actual 1Q FY2026 Actual YOY Change Sales 25.9 32.6 +6.7 OP 8.2 10.7 +2.5 Fixed cost & others 【1Q】 up ¥1.6 billion Semiconductor market growth across a wide range of technology nodes Significant sales growth in Multi-layer process materials, ARC®, and EUV materials driven by higher customer fab utilization in Asia. Positive FX impact. 3D packaging process materials for back-end process sales solid Fixed cost & others up ¥1.2 billion Semis Materials Display demand down, particularly in IT applications, due to rising memory prices Photo IPS sales up: Lower demand for monitor and tablet applications due to rising memory prices, offset by a rebound in smartphone from the weak level in 1Q FY2025 VA for TV sales down Display Materials Inorganic Materials 【1Q】 Sales & OP up 【1Q】 Sales & OP down 【1Q】 Sales & OP up 25年度1Qに弱含んだスマホ向けがやや回復、の代案 Photo IPS sales up: Lower demand for monitor and tablet applications due to rising memory prices, offset by higher smartphone demand compared with the weak level in 1Q FY2025. Sales up in SNOWTEX (non-polishing and polishing), Organo/Monomer Sol and Oilfield materials SNOWTEX (polishing) sales up: Higher demand for CMP slurry raw materials driven by growing semiconductor demand Organo/Monomer Sol sales up: Higher demand for ICT applications (data-center related) and enameled wire for EV 3D packaging process materials for back-end processについて、 表現が長く、processが繰り返されるのが気になるという指摘あり（上出さん） 2Q決算以降、最初だけ上記のように記載して、2回目以降は“for back-end process”を削ったり、 3D packaging process materials を3D packaging materialsに省略してもよいかもしれない。製品名を省略する際 は注記が必要かも？
Page 17
Performance Materials 17 1Q FY2026 Compared to Outlook (¥billion) 1Q FY2026 Outlook 1Q FY2026 Actual vs. Outlook Sales 29.6 32.6 +3.0 OP 8.3 10.7 +2.4 Fixed cost & others 【1Q】 less than outlook ¥1.0 billion (some Fixed cost & others in Semis shifted to 2Q or later) Sales above target, driven by Multi-layer process materials and ARC®, supported by higher customer fab utilization in Asia and positive FX impact 3D packaging process materials for back-end process sales in line with target Fixed cost & others less than outlook ¥1.0 billion Details: fixed cost less than outlook ¥0.2 billion inventory adjustment cost less than ¥0.8 billion (shifted to 2Q or later) Photo IPS and VA sales in line with target Semis Materials Display Materials Inorganic Materials 【1Q】 Sales & OP above target 【1Q】 Sales & OP above target 【1Q】 Sales in line with target, OP slightly below target Sales above target in SNOWTEX (non-polishing and polishing) and Organo/Monomer Sol SNOWTEX (polishing) sales above target: Higher demand for CMP slurry raw materials driven by growing semiconductor demand Organo/Monomer Sol sales above target: Higher demand for ICT applications (data-center related) and enameled wire for EV
Page 18
Agrochemicals 18 58.1 62.7 64.0 63.8 65.8 81.6 82.1 86.2 96.2 97.2 16.4 18.4 19.3 18.2 18.1 23.1 23.4 25.9 26.0 27.0 28.2% 29.3% 30.2% 28.5% 27.5% 28.3% 28.5% 30.0% 27.0% 27.8% 0% 5% 10% 15% 20% 25% 30% 35% 40% 45% 0.0 20.0 40.0 60.0 80.0 100.0 120.0 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025 FY2026E Sales OP OP Margin Overview ▍ Agrochemicals – Recent Financial Performance1 （¥billion） 1 ▍ FY2026 Outlook by Segment (¥billion) OPSales 289.7 Agrochemicals 97.2 Performance Materials 126.1 Chemicals 41.4 66.8 Agrochemicals 27.0 Chemicals 1.3 Performance Materials 38.6 Healthcare 5.5 Others 19.5 Healthcare 1.1 Others -1.2 1. FY2025- : New OP method adopted. FY2024 Actual have been restated based on the new method.
Page 19
Agrochemicals 19 Sales Growth Rate of Main Products （before discount） 1. ROUNDUP AL for general household account for 34% of total ROUNDUP sales (1Q FY2026 Actual) 2. VERDAD was launched in 4Q FY2024 3. Total segment sales include discount Reference ROUNDUP Business Briefing （January 22, 2020） Agrochemicals Business Briefing （January 13, 2026） as of Nov 2025 Main Products （Agro: in order of FY2024 Sales amount） Types FY2025 Actual FY2026 Outlook YOY YOY 1H 3Q 4Q 2H Total 1Q 2Q 1H 2H Total ROUNDUP1 Herbicide ALTAIR Herbicide - - - - GRACIA Insecticide - - - - - LEIMEY Fungicide - - - TARGA Herbicide - - - - - - - PERMIT Herbicide - - - DITHANE Fungicide - - - - - - VERDAD Herbicide - Fluralaner Animal products - - Total Segment2 - - - 【1Q】 Sales YOY flat, Sales above target Main Products （Agro: in order of FY2025 Sales amount） Types 1Q FY2026 Actual YOY Change vs. Outlook Agro ROUNDUP1 Herbicide +18% Above ALTAIR Herbicide +8% Above GRACIA Insecticide +12% Above LEIMAY Fungicide -44% Slightly Below TARGA Herbicide -4% In line PERMIT Herbicide -31% Below DITHANE Fungicide -7% In line VERDAD2 Herbicide +569% Above Animal Health Fluralaner Animal Health products -3% Above Total Segment3 - 0% Above ▍1Q FY2026 Actual Sales Composition* *Before discount, excluding Fluralaner ROUNDUP ALTAIR GRACIA LEIMAY PERMIT VERDAD TARGA DITHANE Others
Page 20
Agrochemicals 20 1Q FY2026 YOY Change （¥billion） 1Q FY2025 Actual 1Q FY2026 Actual YOY Change Sales 26.6 26.6 0.0 OP 8.6 8.8 +0.2 【1Q】Sales flat, OP up ROUNDUP Fluralaner ALTAIR, VERDAD GRACIA Sales up (ML and AL: volume down due to unfavorable weather in 1Q FY2025) Sales up (domestic: VERDAD sales expansion) Sales up (domestic: sales up due to increased demand) Sales down (API: sales down, partial shipment shifted from FY2024 to 1Q FY2025, royalties: sales up, partly affected by positive FX impact) LEIMAY Sales down (export: sales down due to decreased demand in Europe caused by weather conditions)
Page 21
Agrochemicals 21 1Q FY2026 Compared to Outlook 1Q FY2026 Outlook 1Q FY2026 Actual vs. Outlook Sales 23.3 26.6 +3.3 OP 7.2 8.8 +1.6 固定費等 【1Q】下ぶれ〇〇億円（増益要因） 【1Q】Sales & OP above target パーミット 上ぶれ（輸出：一部出荷前倒し） パーミットの上ぶれ幅は大きいですが、 1Q2Qの入り繰りで上期では解消、YOYでもコメント無しのため、 予想比からも外しました （¥billion） ROUNDUP Fluralaner ALTAIR, VERDAD GRACIA Sales above target (ML and AL: partial shipment shifted from 2Q) Sales above target (domestic: sales up due to increased demand) Sales above target (domestic: sales up due to increased demand, export: sales up due to increased demand in Asia) Sales above target (API: sales up, royalties: sales up, partly affected by positive FX impact) LEIMAY Sales slightly below target (export: sales down due to decreased demand in Europe caused by weather conditions)
Page 22
Agrochemicals 22 Main Products (No change from the May 2026 announcement) Existing productsNew products ・Pipeline Launch Products Application Product development type Notes 2002 ROUNDUP Herbicide Acquired Acquired domestic business from Monsanto, continuing to grow 2008 LEIMAY Fungicide In-house 2008 STARMITE Insecticide In-house 2009 PULSOR (THIFLUZAMIDE) Fungicide Acquired Acquired world business from Dow 2010 ROUNDUP AL Herbicide In-house For general household shower-type herbicide market, launched ROUNDUP ALⅡ in FY2016 and ALⅢ in FY2017 2011 ALTAIR Herbicide In-house For paddy rice. Launched in Korea in FY2011 and in Japan in FY2012 2013 Fluralaner Animal health product In-house Started to be supplied to MAH1 as the API of BRAVECTO® 2014 BRAVECTO®2 Veterinary medical product for companion animals - Launched in several countries in EU in April 2014, in USA in June 2014 and in Japan in July 2015 2017 TRANSFORM / EXCEED / VIRESCO Insecticide Licensed-in Licensed from Dow 2018 GRACIA Insecticide In-house Effective against a wide range of serious pests, having less negative impact on honeybees. Launched in Korea in FY2018, in Japan in FY2019, and In India and Indonesia in FY2021. Expanding sales countries (expected peak sales ¥12.5 billion) 2019 QUINTEC (QUINOXYFEN) Fungicide Acquired Acquired world business from Corteva. Protective fungicide highly effective in controlling powdery mildew in fruits and vegetables 2020 DITHANE (MANCOZEB) Fungicide Acquired Acquired Japan and Korea business from Corteva in December 2020. Protective fungicide with significant efficacy against various plant diseases in fruits and vegetables 2024 VERDAD (DIMESULFAZET) (NC-653) Herbicide In-house For paddy rice. Effective against resistant weeds, having excellent safety to rice (expected peak sales ¥6.0 billion) 2027 RYZONIC (IPTRIAZOPYRID) (NC-656) Herbicide In-house Our first foliar application rice herbicide with excellent efficacy against resistant grass weeds (expected peak sales ¥15.0 billion3) 2028 PREXIO (FENMEZODITIAZ) (NC-520) Insecticide Joint development Insecticide for paddy rice co-developed with BASF. Highly effective against planthoppers (expected peak sales ¥2.5 billion including mixture products) Expected peak sales of new products ¥41.0 billion3 1. MAH: MSD Animal Health, the global animal health business unit of Merck 2. BRAVECTO®: the product name developed by MAH, containing the active substance Fluralaner 3. Expected peak sales of RYZONIC were revised upward from ¥10.0 billion to ¥15.0 billion in January 2026
Page 23
Agrochemicals 23 API of Animal Health Product Fluralaner (No change from the May 2026 announcement) ◼ Developed and launched by MAH１ ◼ Veterinary medical products providing 12 weeks2 of continuous protection for dogs and cats against fleas and ticks with immediate effect, nearly 3 times longer than any monthly products in the market. ◼ Chewable tablet for dogs launched in: ⚫ April 2014 EU, thereafter, USA, Japan, etc. ⚫ July 2020 monthly chews for puppies in USA ◼ Spot-on solution for dogs and cats launched in: ⚫ July 2016 EU, thereafter, USA, Japan, etc. ◼ Injectable solution for dogs (BRAVECTO® Quantum) ⚫ Providing 12 months3 of continuous protection ⚫ Launched in Australia in June 2024, and thereafter, in Europe, etc. ⚫ Launched in USA in August 2025 ⚫ Launched in Japan in March 2026 ◼ Poultry medicine against red mite (administered via drinking water) ⚫ Launched in EU in 2017, thereafter, Korea, Middle East and Japan. ◼ Cattle medicine ⚫ Launched in Brazil in 2022, thereafter Mexico ◼ Sheep medicine ⚫ Launched in Australia and New Zealand in 2023 ◼ BRAVECTO® Plus ⚫ spot-on solution for cats ⚫ Launched in EU in July 2018, thereafter, USA, Japan, etc. ◼ BRAVECTO® TriUNO ⚫ Three-in-one chewable tablet for dogs ⚫ Providing 1 month of continuous protection ⚫ Approved in EU countries and Latin America in October 2024 ◼ Invented by Nissan Chemical and supplied to MAH1 as the active pharmaceutical ingredient of BRAVECTO® and EXZOLT® ◼ Currently, BRAVECTO® series and EXZOLT® are available in more than 100 countries ◼ Compound patent ⚫ Fluralaner’s compound patent expires in March 2025, but many countries have the patent term extension system • Some EU countries including UK, France, and Germany – already extended to February 2029 • USA - extended to June 2027 IV. EXZOLT® I. Fluralaner 1. MAH: MSD Animal Health, the global animal health business unit of Merck 2. 8 weeks for Rhipicephalus sanguineus ticks 3. 11 months for Rhipicephalus sanguineus ticks II. BRAVECTO® for Ecto III. BRAVECTO® for Endecto I. Fluralaner II. BRAVECTO® for external parasites (Ecto) III. BRAVECTO® for both internal and external parasites (Endecto) IV. EXZOLT® ◼ BRAVECTO® series and EXZOLT®, which contain the active pharmaceutical ingredient of Fluralaner invented by Nissan Chemical, are currently available in more than 100 countries. ◼ BRAVECTO® 's greatest feature is its effectiveness, which lasts up to 12 weeks (competing products last up to about 1 month) ◼ Long-term supply agreement with MAH1 for Fluralaner extended, joint R&D to create new animal health products (News release on April 11, 2025)
Page 24
Agrochemicals 24 Sales Trend of Fluralaner (No change from the May 2026 announcement) ▍Nissan Chemical’s Revenues are Consisted from Following Two Factors ・Sales of Fluralaner to MAH1 as API2 of BRAVECTO® and EXZOLT® products ・Running royalties received from MAH ▍FY2022 - FY2026 Sales Trend (including royalties) ◼ FY2025 actual is +10% YOY , with API sales increase by +37% due to shipments shifted from FY2024. The actual exchange rate is ¥151/$. ◼ FY2026 outlook is flat YOY . The assumed exchange rate is ¥150/$. ▍BRAVECTO® series R&D MAH is developing new parasiticides for pets with Fluralaner as the API, and expanding the number of the registered countries for existing products. ▍FY2025 - FY2026 Quarterly Sales (including royalties) 1. MAH: MSD Animal Health, the global animal health business unit of Merck 2. API: Active Pharmaceutical Ingredient FY2022 Actual FY2023 Actual FY2024 Actual FY2025 Actual FY2026 Outlook Our Fluralaner sales tend to be larger in 1H due to demand trends at MAH FY2025 FY2026 Outlook 4Q 3Q 2Q 1Q as of Nov 2025 as of Nov 2025 +12% (API sales +47%, including partial shipment shifted from FY2024）
Page 25
Chemicals 25 Overview 34.9 35.7 34.3 31.9 37.6 39.0 35.6 37.8 39.3 41.4 3.4 3.0 1.3 1.5 3.8 1.4 0.0 0.4 1.1 1.3 9.7% 8.4% 3.8% 4.7% 10.1% 3.6% 0.1% 1.1% 2.8% 3.1% 0% 2% 4% 6% 8% 10% 12% 14% 16% 18% 20% FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025 FY2026E Sales OP OP margin ▍ Chemicals – Recent Financial Performance1 （¥billion） 1. FY2025- : New OP method adopted. FY2024 Actual have been restated based on the new method. 1 ▍ FY2026 Outlook by Segment (¥billion) OPSales 289.7 Agrochemicals 97.2 Performance Materials 126.1 Chemicals 41.4 66.8 Agrochemicals 27.0 Chemicals 1.3 Performance Materials 38.6 Healthcare 5.5 Others 19.5 Healthcare 1.1 Others -1.2 2. Organizational changes in Healthcare and Planning and Development division were implemented in April 2022. Figures for FY2020 and before are based on the pre-restructuring organization, while figures after FY2020 reflect the post-restructuring structure 変更なし
Page 26
Chemicals 26 1Q FY2026 YOY Change, Compared to Outlook （¥billion） （¥billion） 【1Q】 Sales & OP up ▍YOY Change ▍Compared to Outlook In Fine Chemicals, OP flat due to fixed costs & others up despite sales up in TEPIC and environmental related products In Basic Chemicals, OP up due to sales up in nitric acid products (recovery from mechanical trouble in 1Q FY2025) and high purity sulfuric acid (demand increase for semiconductors) In Fine Chemicals, OP above target due to sales above target in environmental related products and TEPIC etc. In Basic Chemicals, OP below target due to fixed costs & others more than outlook despite sales above target in nitric acid products and urea/AdBlue® 【1Q】 Sales above target, OP below target 1Q FY2025 Actual 1Q FY2026 Actual YOY Change Sales 9.3 10.5 +1.2 Fine Chemicals 3.4 4.0 +0.6 Basic Chemicals 5.9 6.5 +0.6 OP 0.7 0.9 +0.2 1Q FY2026 Outlook 1Q FY2026 Actual vs. Outlook Sales 9.9 10.5 +0.6 Fine Chemicals 3.5 4.0 +0.5 Basic Chemicals 6.4 6.5 +0.1 OP 1.0 0.9 -0.1 recovery from mechanical trouble in 1Q FY2025 ⇒26年度は25年度トラブル影響なしで実績が回復している為 recoveryと表現したがどう か？25年2Q資料でプラントトラブルは以下の通り訳されていたので、表現を合わせて Mechanical troubleとする。
Page 27
Chemicals 27 Flow Chart of Selected Basic and Fine Chemicals Products (No change from the May 2026 announcement) sulfur urea melamine cyanurate isocyanuric acid environmental related product nitric acid TEPIC high purity sulfuric acid AdBlue®ammonia high purity ammonia chlorine sulfuric acid (Semiconductor cleaners) Domestic largest manufacturer (agent used for sterilizing, disinfectant for swimming pool and septic tanks, etc.) (general applications: painting electronic materials: solder resist, LED sealants) (flame retardant)（agent used for gallium nitride； LED materials） (solution of urea in demineralised water for diesel vehicles) production terminated in June 2022 purchase melamine from outside （adhesive agent） HI-LITE environmental related products natural gas Mainly sourced outside the Middle East (nitric acid, nitrous acid and nitrate of soda: metal dissolution, surface treatment, antifoam agent, etc.) Purchased materials Basic Chemicals Fine Chemicals ◼ Core products are ammonia related products and sulfuric acid related products ◼ FY2025 ammonia domestic production capacity share 11% ◼ Focus on high value-added products, such as high purity sulfuric acid, instead of pursuing scale melamine 変更なし
Page 28
Healthcare 28 7.5 7.0 7.0 6.7 6.6 6.7 6.3 6.0 5.2 5.5 1.2 1.0 0.9 0.4 2.8 3.0 2.8 1.9 1.4 1.1 16.0% 14.3% 12.9% 6.0% 42.4% 44.8% 44.4% 31.7% 26.9% 20.0% 0% 10% 20% 30% 40% 50% 0.0 2.0 4.0 6.0 8.0 10.0 12.0 14.0 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025 FY2026E Sales OP OP Margin ▍ Healthcare – Recent Financial Performance1・2 （¥billion） Overview 1. FY2025- : New OP method adopted. FY2024 Actual have been restated based on the new method 2. Organizational changes in Healthcare and Planning and Development division were implemented in April 2022. Figures for FY2020 and before are based on the pre-restructuring organization, while figures after FY2020 reflect the post-restructuring structure. 1 ▍ FY2026 Outlook by Segment (¥billion) OPSales 289.7 Agrochemicals 97.2 Performance Materials 126.1 Chemicals 41.4 66.8 Agrochemicals 27.0 Chemicals 1.3 Performance Materials 38.6 Healthcare 5.5 Others 19.5 Healthcare 1.1 Others -1.2 変更なし
Page 29
Healthcare 29 1Q FY2026 YOY Change, Compared to Outlook （¥billion） 【1Q】 Sales & OP up OP up due to sales up in Healthcare & Custom Chemicals （¥billion） 【1Q】 Sales above target, OP in line with target ▍YOY Change ▍Compared to Outlook 1Q FY2025 Actual 1Q FY2026 Actual YOY Change Sales 1.6 1.9 +0.3 OP 0.5 0.7 +0.2 1Q FY2026 Outlook 1Q FY2026 Actual vs. Outlook Sales 1.8 1.9 +0.1 OP 0.7 0.7 0.0
Page 30
30 1Q FY2026 Financial Results YOY Change by Segment 1. Including inter-segment sales/transfers 2. Trading: Nissei Corporation, Others: Nissan Butsuryu, Nissan Green & Landscape, Nissan Engineering, NC Tokyo Bay, Nippon Polytech, Nihon Hiryo, Adjustment: Planning & Development Division and others （¥billion） 1Q FY2025 Actual 1Q FY2026 Actual YOY Change Performance Materials Sales 25.9 32.6 +6.7 (+26%) OP 8.2 10.7 +2.5 (+30%) Agrochemicals Sales 26.6 26.6 0.0 (0%) OP 8.6 8.8 +0.2 (+2%) Chemicals Sales 9.3 10.5 +1.2 (+13%) OP 0.7 0.9 +0.2 (+23%) Healthcare Sales 1.6 1.9 +0.3 (+18%) OP 0.5 0.7 +0.2 (+50%) Trading, Others, Adjustment Sales 6.5 7.2 +0.7 OP 0.1 0.8 +0.7 Total Sales 69.9 78.8 +8.9 (+13%) OP 18.1 21.9 +3.8 (+21%)
Page 31
31 1Q FY2026 Compared to Outlook by Segment （¥billion） 1. Including inter-segment sales/transfers 2. Trading: Nissei Corporation, Others: Nissan Butsuryu, Nissan Green & Landscape, Nissan Engineering, NC Tokyo Bay, Nippon Polytech, Nihon Hiryo, Adjustment: Planning & Development Division and others FY2025 Outlook as of Nov 2025 FY2025 Actual vs. Outlook 1H Actual 3Q 4Q 2H Total 1H 3Q 4Q 2H Total 3Q 4Q ・ - - - - - (- - - - - (- - - (- - - - - - - - - 1Q FY2026 Outlook 1Q FY2026 Actual vs. Outlook Performance Materials Sales 29.6 32.6 +3.0 (+10%) OP 8.3 10.7 +2.4 (+29%) Agrochemicals Sales 23.3 26.6 +3.3 (+14%) OP 7.2 8.8 +1.6 (+23%) Chemicals Sales 9.9 10.5 +0.6 (+6%) OP 1.0 0.9 -0.1 (-13%) Healthcare Sales 1.8 1.9 +0.1 (+3%) OP 0.7 0.7 0.0 (+6%) Trading, Others, Adjustment Sales 4.5 7.2 +2.7 OP -0.4 0.8 +1.2 Total Sales 69.1 78.8 +9.7 (+14%) OP 16.8 21.9 +5.1 (+30%)
Page 32
32 C o n t e n t s 03 ESG Topics P32
Page 33
33 June 2026 ESG E (Environment） S （Social） G (Governance) Announced its Diversity Statement and Diversity VisionApril 2021 Sep 2025 June 2022 Reduced GHG emissions by melamine production stop (26,000 tons, equivalent to about 7% of FY2018) Established Nomination and Remuneration Advisory Committee as an optional advisory body of the Board of DirectorsApril 2019 June 2019 Introduced a performance-linked stock compensation plan called a Board Benefit Trust for Board of Directors, etc. “Nissan Bio-Park Nishi-Hongo (Toyama Plant)” and “Onoda Plant Biotope” Certified as “Nationally Certified Sustainably Managed Natural Sites” by the Ministry of the Environment Updated and disclosed “Corporate Governance Report " Decided to work on realization of carbon neutrality by 2050 Established new long-term target for reducing greenhouse gas (GHG) emissions (see p36)May 2022 June 2022 Established Climate Change Committee Oct 2025 Published “Integrated Report 2025 ” Partially revised the officers’ remuneration system to increase the ratio of remuneration in stock. Before the revision: base remuneration 65%, performance-related remuneration 28%, remuneration in stock 7% After the revision1: base remuneration 50%, performance-related remuneration 30%, remuneration in stock 20%2 April 2026 1.The breakdown of performance-related remuneration (90% profit-linked and 10% ESG-linked) remains unchanged. 【申送り事項】 ・2026年6月の株主総会にて、女性監査役（尾関さん）が追加された旨を反映 ・June 2019と April 2026の表記ゆれについて 役員報酬体系の改定について、RemunerationとCompensationが混在している。 Remunerationで統一したいが、既出のプレスでCompensationを使用しているため、 何に合わせるべきか悩ましい。 2. Linked to ROE and TSR based metrics. 2 female Outside Directors appointed (re-elected), as a result, the Board of Directors includes 4 Outside Directors out of 10 2 female Outside Audit & Supervisory Board Member appointed (1 re-elected and 1 newly elected), as a result, the Board of Audit & Supervisory includes 3 Outside Directors out of 4 June 2026
Page 34
34 ◼ January 2023 Acquired twice consecutively ESG Index and Third-party Recognition Certified Health & Productivity Management Organization (White 500) S&P/JPX Carbon Efficient Index Participation in External Initiatives Dow Jones Best-in-Class Asia Pacific Index “Childcare Support Company” Kurumin FTSE MSCI ◼ April 2026 Selected as a constituent for 8 consecutive years, including the former Dow Jones Sustainability Asia Pacific Index ◼ June 2025 Selected as a constituent for 7 consecutive years ◼ June 2026: Selected as a constituent of FTSE4Good Index Series, FTSE Blossom Japan Index for 7 consecutive years ◼ June 2026: Selected as a constituent of FTSE Blossom Japan Sector Relative Index for 5 consecutive years 1. FTSE Russell confirms that Nissan Chemical has been independently assessed according to the index criteria, and has satisfied the requirements to become a constituent of the FTSE Blossom Japan Sector Relative Index. The FTSE Blossom Japan Sector Relative Index is used by a wide variety of market participants to create and assess responsible investment funds and other products. ◼ May 2025: Upgraded from A to AA (MSCI ESG Rating) ◼ June 2025: Selected as a constituent of MSCI Nihonkabu ESG Select Leaders Index for 2 consecutive years 2. THE INCLUSION OF NISSAN CHEMICAL CORPORATION IN ANY MSCI INDEX, AND THE USE OF MSCI LOGOS, TRADEMARKS, SERVICE MARKS OR INDEX NAMES HEREIN, DO NOT CONSTITUTE A SPONSORSHIP, ENDORSEMENT OR PROMOTION OF NISSAN CHEMICAL CORPORATION BY MSCI OR ANY OF ITS AFFILIATES. THE MSCI INDEXES ARE THE EXCLUSIVE PROPERTY OF MSCI. MSCI AND THE MSCI INDEX NAMES AND LOGOS ARE TRADEMARKS OR SERVICE MARKS OF MSCI OR ITS AFFILIATES.ｚ ◼ March 2026: Acquired for 10 consecutive years Morningstar ◼ December 2025: Selected as a constituent of Japan ex-REIT Gender Diversity Tilt Index for 3 consecutive years CDP ◼ January 2026: Selected as A List for CDP Water Security 【申し送り事項】 ・FTSEの組み入れが確定したので更新（7年連続、5年連続等） 次回以降、TDKのような資料に変えることはできないか？ ・Morningstarはロゴを当社では取得しないのか？ ・DJBIC（旧DJSI）からロゴが発行されなくなったがどうすればよいか ・FTSEの注釈は必須なのか？（TDKではMSCIのみ注釈載せている）
Page 35
35 Specified materiality that we should engage to realize corporate image of 2027. Aim to have sustainable growth with society by promoting initiatives. Provision of New Value for Helping to Enrich People’s Lives Strengthening of Nissan Chemical’s Business Base Continuous Improvement of Responsible Care Activities 1 2 3 Nissan Chemical Sustainable Agenda1 Rate of total sales of products and services that contribute to solving social issues in consolidated net sales 60% or more 1. A plan to pursue “what we can do for the future of the globe and human ”by providing products and services that contribute to solving social issues GHG Emission Target Reduced by 30% or more compared to FY2018 Our Materiality Strengthening of Corporate Governance, Risk Management and Compliance Promote Diversity Proportion of female researchers 18% or more Materiality (revised in Vista2027 Stage II) Personnel retention and trainings Positive response rate in survey of employee attitude 65% or more (revised upward from maintain at least 55%) 【申し送り事項】 タイトルから「 (No change from the May 2025 announcement)」を削除
Page 36
36 ◼ To achieve carbon neutrality by 2050, focus on initiatives such as improving production technology and adopting renewable energy, in addition to conventional efforts ◼ FY2027 GHG emissions target is expected to achieve at least a 30% reduction compared to FY2018 (Scope 1+2, non-consolidated basis). In FY2025, GHG emissions temporarily increased, reflecting the impact of mechanical trouble at the nitric acid plant in 1Q. Reduction of GHG Emissions 363 327 318 345 328 285 278 331 254 0 100 200 300 400 FY2018 Actual FY2019 Actual FY2020 Actual FY2021 Actual FY2022 Actual FY2023 Actual FY2024 Actual FY2025 Actual FY2027 Target (Thousands of tons of -CO2e) ◼ Zero N2O emissions from nitric acid plants (Planned investment of ¥830 million, variable cost of ¥70 million/year) ◼ Melamine production shutdown ◼ Converting fuels at Onoda Plant ◼ Promoting reduction of GHG emissions through full-scale introduction of ICP ◼ Reduction of CFC equipment ◼ Upgrade to energy-efficient equipment Initiatives in Medium-Term Plan Vista2027 (FY2022-2027) △30% FY 2019 2020 2021 2022 2023 2024 Nissan Chemical 346 337 364 346 305 315 Average of 4 major general chemical manufacturers 9,275 8,928 9,226 8,390 7,803 7,691 ▍Comparison of GHG emissions with general chemical manufacturers (consolidated basis) （Thousands of tons -CO2e） ◼ GHG emissions target for FY2027: Reduce by at least 30% compared to FY2018 (SCOPE1+2, non-consolidated basis) ▍Our GHG emissions reduction target (Scope 1+2, non-consolidated basis) 初期案 ◼ On track to achieve the FY2027 GHG emissions target : Reduce by at least 30% compared to FY2018(Scope 1+2, non-consolidated basis). ◼ In FY2025, GHG emissions temporarily increased in 1Q, reflecting the impact of mechanical trouble at the nitric acid plant. ⇒FY2027 targetとIn FY2025の文章の始まり方が違うことに違和感があり修正。On track to ～ は分かりやすい表現だが、前後の文章と合わせるためにThe FY2027 GHG emissions targetを 主語とする形に修正する。
Page 37
37 C o n t e n t s 04 Appendix P37
Page 38
38 1. Including inter-segment sales/transfers 2. Trading: Nissei Corporation, Others: Nissan Butsuryu, Nissan Green & Landscape, Nissan Engineering, NC Tokyo Bay, Nippon Polytech, Nihon Hiryo, Adjustment: Planning & Development Division and others Quarterly Sales Trend by Segment (FY2023 - 1Q FY2026) (¥billion) FY2023 Actual FY2024 Actual FY2025 Actual FY2026 Actual 1Q 2Q 3Q 4Q Total 1Q 2Q 3Q 4Q Total 1Q 2Q 3Q 4Q Total 1Q Performance Materials 20.8 19.7 21.4 22.7 84.6 23.5 25.1 25.6 25.9 100.1 25.9 28.5 28.6 30.4 113.4 32.6 Agrochemicals 18.8 16.5 13.2 33.6 82.1 20.4 18.8 14.6 32.4 86.2 26.6 15.7 19.2 34.7 96.2 26.6 Chemicals 9.1 8.8 9.6 8.1 35.6 8.9 9.0 10.2 9.7 37.8 9.3 9.5 10.1 10.4 39.3 10.5 Fine Chemicals 3.0 3.0 3.0 2.6 11.6 3.1 3.2 3.4 3.2 12.9 3.4 3.4 3.2 3.7 13.7 4.0 Basic Chemicals 6.1 5.8 6.6 5.5 24.0 5.8 5.8 6.8 6.5 24.9 5.9 6.1 6.9 6.7 25.6 6.5 Healthcare 2.0 1.5 1.3 1.5 6.3 1.5 1.8 1.1 1.6 6.0 1.6 1.2 1.2 1.2 5.2 1.9 Trading 24.3 24.5 28.3 26.7 103.8 27.5 28.8 30.8 30.1 117.2 30.0 28.8 35.7 34.4 128.9 38.3 Others 6.4 5.9 6.0 11.8 30.1 6.3 5.7 8.8 8.4 29.2 7.9 6.9 7.7 9.3 31.8 8.9 Adjustment -26.5 -26.1 -30.2 -33.0 -115.8 -29.4 -29.7 -34.5 -31.5 -125.1 -31.4 -30.4 -37.2 -36.2 -135.2 -40.0 Total 54.9 50.8 49.6 71.4 226.7 58.7 59.5 56.6 76.6 251.4 69.9 60.2 65.3 84.2 279.6 78.8 FY2026 Outlook 1Q 2Q 2H Total 29.6 30.6 65.9 126.1 23.3 15.9 58.0 97.2 9.9 9.7 21.8 41.4 3.5 3.3 7.2 14.0 6.4 6.4 14.6 27.4 1.8 0.7 3.0 5.5 32.4 31.3 74.1 137.8 8.8 10.4 18.3 37.5 -36.7 -36.2 -82.9 -155.8 69.1 62.4 158.2 289.7 3Q 4Q Total
Page 39
39 Quarterly OP Trend by Segment (FY2023 - 1Q FY2026) (¥billion) FY2023 Actual FY2024 Actual FY2025 Actual FY2026 Outlook 1Q 2Q 3Q 4Q Total 1Q 2Q 3Q 4Q Total 1Q 2Q 3Q 4Q Total 1Q Performance Materials 6.5 4.6 6.3 5.1 22.5 7.1 7.4 8.0 6.8 29.3 8.2 9.2 9.4 8.5 35.3 10.7 Agrochemicals 6.6 5.0 2.9 8.9 23.4 7.0 7.4 3.8 7.7 25.9 8.6 3.4 5.0 9.0 26.0 8.8 Chemicals 0.9 -1.0 0.4 -0.3 0.0 0.7 -1.0 0.5 0.2 0.4 0.7 -0.8 0.3 0.9 1.1 0.9 Healthcare 1.1 0.7 0.5 0.5 2.8 0.6 0.7 0.4 0.2 1.9 0.5 0.2 0.4 0.3 1.4 0.7 Trading 0.9 0.9 1.0 0.9 3.7 1.0 1.0 1.1 1.0 4.1 1.1 0.9 0.9 0.9 3.8 1.4 Others 0.2 0.0 -0.3 0.7 0.6 0.1 -0.1 0.1 0.5 0.6 0.5 0.3 0.2 1.0 2.0 0.5 Adjustment -1.2 -1.1 -1.5 -1.0 -4.8 -2.1 -1.5 -1.1 -0.7 -5.4 -1.5 -1.7 -0.8 -2.0 -6.0 -1.1 Total 15.0 9.1 9.3 14.8 48.2 14.4 13.9 12.8 15.7 56.8 18.1 11.5 15.4 18.6 63.6 21.9 FY2026 Outlook 1Q 2Q 2H Total 8.3 9.5 20.8 38.6 7.2 3.9 15.9 27.0 1.0 -0.7 1.0 1.3 0.7 -0.2 0.6 1.1 0.8 0.8 1.9 3.5 0.4 0.5 0.8 1.7 -1.6 -1.9 -2.9 -6.4 16.8 11.9 38.1 66.8 1. Trading: Nissei Corporation, Others: Nissan Butsuryu, Nissan Green & Landscape, Nissan Engineering, NC Tokyo Bay, Nippon Polytech, Nihon Hiryo, Adjustment: Planning & Development Division and others 2. FY2025- : New OP method adopted. FY2024 Actual have been restated based on the new method.
Page 40
40 Segment Products Main Applications Performance Materials Semis Materials ARC®(ArF, KrF) bottom anti-reflective coating for semiconductors OptiStack® Multi-layer process materials for semiconductors (Si-HM: Silicon Hard Mask / SOC: Spin-On Carbon ) EUV materials EUV process materials (Under-Layer/Si-HM) 3D packaging process materials Temporary bonding materials Display Materials SUNEVER LCD alignment coating (Main Mode) VA (Vertical Alignment) TV IPS (In-Plane Switching) Smartphone, Tablet, PC, Monitor, Automobile Inorganic Materials SNOWTEX water dispersed colloidal silica sol for polishing silicon wafers, special steel sheets Organo/Monomer Sol film coating, antistatic interference shielding, electronic printing materials, resin additive Oilfield materials for enhancing oil recovery Agrochemicals Herbicide TARGA soybean, rapeseed, sugarbeet PERMIT corn, sugarcane, rice ROUNDUP non-selective herbicide for orchard, noncrop land ALTAIR rice VERDAD rice Insecticide GRACIA vegetables, tea, fruits Fungicide LEIMAY potato, vegetables, grape DITHANE (MANCOZEB) fruits, vegetables Animal health product Fluralaner active substance of BRAVECTO® (veterinary medical product for dogs and cats) and EXZOLT® (for poultry, cattle, and sheep) Chemicals Fine Chemicals TEPIC epoxy compound for LED sealants, solder resist, painting Melamine cyanurate flame retardant Environmental related products agent used for sterilizing, disinfectant for swimming pool and septic tanks, etc. FINEOXOCOL cosmetics, lubricants, adhesive Basic Chemicals AdBlue® solution of urea in demineralised water for diesel vehicles to reduce NOx High purity sulfuric acid agents used for cleaning semiconductors Ammonia, Sulfuric acid, Nitric acid, Urea Healthcare LIVALO API anti-cholesterol drug Custom Chemicals custom manufacturing and solution proposal business for pharmaceutical companies 1. ARC® and OptiStack® are registered trademark of Brewer Science, Inc. 2. BRAVECTO® and EXZOLT® are registered trademark of a subsidiary of Merck & Co., Inc. 3. AdBlue® is a registered trademark of German Automobile Industry Association (Verband der Automobilindustrie). Main Products by Segment 【申送り事項】 基礎化学品 メラミン削除：「Melamine (sales ended in December 2022)」 半導体材料について以下の通り更新（半導体営業部より指示あり） Multi-Layer Process Materials (ハイフンが必要) SOC: Spin-On Carbon (ハイフンが必要) Si-HM: Silicon Hard Mask (SiliconとHardの間にハイフンは不要) EUV under-layer (ハイフンが必要) 3D Packaging process materials (Temporary bonding materials) →AdhesiveではなくBonding
Page 41
41 Disclaimer and Copyright The forward looking statements in this material are based on information available at the time of preparation of the material. Although they reflect our current expectations, these statements are not guarantees of future performance, but include a number of risks and uncertainties. Actual results may largely differ from these statements due to various factors which may be beyond company control. No information in this material is provided as an offer to buy or sell the shares of the company. We urge users of the material to make investment decision based upon own judgment. All rights reserved to Nissan Chemical Corporation.